

BIO IMAGING TECHNOLOGIES INC

Form 8-K

October 05, 2007

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K  
CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): October 4, 2007

**Bio-Imaging Technologies, Inc.**

(Exact Name of Registrant as Specified in Charter)

Delaware

1-11182

11-2872047

(State or Other Jurisdiction  
of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

826 Newtown-Yardley Road, Newtown, PA

18940

(Address of Principal Executive Offices)

(Zip Code)

(267) 757-3000

(Registrant's telephone number,  
including area code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

On October 4, 2007, Bio-Imaging Technologies, Inc., a Delaware corporation (the Company), issued a press release to report that CapMed, a division of the Company, entered into a strategic alliance with Microsoft Corporation, for the Company to offer its emergency personal health record. The Company did not receive any upfront payments, but it will receive payments based upon a per user basis. No other terms of the agreement were disclosed at this time. Any revenue received will be reported in the Company's periodic filings with the Securities and Exchange Commission (the SEC). The agreement will be filed as an exhibit to the Company's periodic report with the SEC if it becomes a material agreement. The full text of the press release is furnished with this current report on Form 8-K as Exhibit 99.1.

The information in this current report on Form 8-K and the press release shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release of Bio-Imaging Technologies, Inc. dated October 4, 2007.

-2-

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

**BIO-IMAGING TECHNOLOGIES, INC.**

Dated: October 5, 2007

By: /s/ Mark L. Weinstein  
Name: Mark L. Weinstein  
Title: President & CEO